Chidamide is a histone deacetylase inhibitor (HDACI) that downregulates WTAP and METTL3 to induce c-MET mRNA hypomethylation, reducing the expression of c-MET, which helps to enhance the sensitivity to the ALK/ROS1/c-MET kinase inhibitor crizotinib in the treatment of non-small cell lung cancer (NSCLC) with high expression of c-MET [65]. Here, WTAP is linked to non-small cell lung carcinoma.